Taysha Gene Therapies develops gene therapies for severe brain disorders, with its lead candidate aimed at Rett syndrome. It last closed at $4.00 on Nov 17, down 1.48% on the day. TSHA last reported earnings on Tue, Aug 11, 2026.
TSHA · as of the Nov 17 close · updated after every close
Downtrend
The stock is 4% below its 20 day and 11% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot S1 at $3.93, and the nearest resistance the Pivot R1 at $4.08.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$7.3052 week high+82.5%
$5.29200 day average+32.3%
$5.24100 day average+31.0%
$4.4350 day average+10.7%
$4.26Swing high (Oct 21)+6.5%
$4.1520 day average+3.8%
$4.08Pivot R1+2.0%
$4.00Pivot+0.0%
$4.00Last close
$3.93Pivot S1−1.7%
$3.92Swing low (Nov 3)−2.0%
$3.4652 week low−13.5%
Indicators
RSI (14)
41.94
Middle of its range
Neutral
MACD
-0.08
Above its signal line
Bullish
Stochastic
21.9
Middle of its range
Neutral
ADX (14)
14.4
No clear trend
Williams %R
-86.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-102.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−2.2%
Change over 10 sessions
Bearish
ATR (14)
$0.27
Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityLow, 16.1%/day
Key levels
$7.3052 week high+82.5%
$5.29200 day average+32.3%
$5.24100 day average+31.0%
$4.4350 day average+10.7%
$4.26Swing high (Oct 21)+6.5%
$4.1520 day average+3.8%
$4.08Pivot R1+2.0%
$4.00Pivot+0.0%
$4.00Last close
$3.93Pivot S1−1.7%
$3.92Swing low (Nov 3)−2.0%
$3.4652 week low−13.5%
Indicators
RSI (14)
38.61
Weak, oversold below 30
Neutral
MACD
-0.40
Below its signal line
Bearish
Stochastic
21.2
Middle of its range
Neutral
ADX (14)
23.4
Weak trend
Williams %R
-82.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-95.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−20.3%
Change over 10 sessions
Bearish
ATR (14)
$0.64
Typical daily range, 16.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for TSHA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TSHA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow TSHA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How TSHA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TSHA is in one of them and how their past TSHA trades turned out.
Taysha Gene Therapies is a biotechnology company based in Dallas, Texas, that develops gene therapies for severe diseases of the central nervous system. Its lead candidate, TSHA-102, is being tested for Rett syndrome, a genetic disorder that mainly affects girls and causes loss of speech, hand use and motor skills. The treatment is still in clinical trials, and its intended users are patients with Rett syndrome and their caregivers.